HL435

HL435 (H27) (0-1000 nM; 1-24 h) potently degrades BRD4 in MDA-MB-231 and MCF-7 cells, with DC₅₀ values of 11.9 nM and 21.9 nM, respectively, and a maximum degradation efficiency of >99%^[1].
HL435 (0-1.0 μM; 6 h) induces BRD4 degradation in MDA-MB-231 cells as well as WT-, ATG5^KO-, and ATG4B^KO-HeLa cells, and this process is independent of the autophagy-lysosome pathway^[1].
HL435 (0-2.0 μM; 6-8 h) induces BRD4 degradation in MDA-MB-231 and HEK293T cells via the ubiquitin-proteasome system, a process that requires activation of functional Cullin-RING E3 ligases^[1].
HL435 (50-5000 nM; 6-24 h) recruits the CRL4_DCAF11 E3 ubiquitin ligase complex, mediates proteasomal degradation of BRD4 in CRISPRi HEK293T cells, and forms a ternary complex with BRD4 and DCAF11^[1].
HL435 (48 h) potently inhibits the proliferation of 22RV1, MDA-MB-31, MCF7, and A549 cells, with IC₅₀ values of 8.7, 205, 378, and 1380 nM, respectively^[1].
HL435 (0.25-1.5 μM; 24 h) induces concentration-dependent cell cycle arrest in MCF-7 cells, blocking G0/G1 phase transition at low concentrations and G2/M phase transition at high concentrations^[1].
HL435 (0.5-1.0 μM; 24-36 h) potently induces apoptosis in MDA-MB-231 cells, with the apoptosis rate reaching 55.9% upon treatment with 1.0 μM for 36 h, and activates caspase-9 as well as induces PARP1 cleavage^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.